Moleculin Biotech - MBRX

05/29/2026

"This poster presentation adds significant momentum to the growing clinical evidence supporting Annamycin’s differentiated profile,” said Walter Klemp, Chairman and CEO of Moleculin Biotech. Read more about the data recently presented at : https://bit.ly/3S9yy6z

05/29/2026

Moleculin today announced new data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting further reinforcing the differentiated cardiac safety profile of its lead drug candidate, Annamycin (also known as “L-Annamycin” or “naxtarubicin”). Read more: https://bit.ly/3S9yy6z

05/26/2026

We will be presenting at the 2026 ASCO Annual Meeting, taking place May 29–June 2 in Chicago, IL.

Join us on May 30 from 1:30 PM to 4:30 PM CDT as we present in the Poster Session: Symptom Science and Palliative Care. Visit us at Poster Board #8 to learn more about our latest data in AML. We look forward to connecting with the oncology community.

05/22/2026

“Acceptance of these findings at ASCO highlights the growing body of evidence supporting the differentiated safety profile of Annamycin,” said Walter Klemp, Chairman and CEO of Moleculin. Read more about the upcoming presentation: https://bit.ly/4nLJROe

05/22/2026

Moleculin today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as “L-Annamycin” or “naxtarubicin”), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. Read more: https://bit.ly/4nLJROe

05/18/2026

In Case You Missed It:

released its latest CEO Corner, where CEO Walter Klemp highlights Annamycin’s differentiated, non-cardiotoxic profile and its potential to expand treatment options in oncology.

Watch here: https://vimeo.com/1180604943/304f2fab03?share=copy&fl=sv&fe=ci

Walter Klemp, Moleculin Chief Executive Officer, highlights the differentiated safety profile of Annamycin, emphasizing its lack of cardiotoxicity which is a significant limitation associated with traditional anthracyclines such as doxorubicin. Annamycin was specifically designed to avoid cardiac da...

05/15/2026

Walter Klemp, Chairman and Chief Executive Officer of Moleculin, comments on enrollment surpassing the first interim analysis threshold in the MIRACLE trial and the Company's belief in Annamycin's potential to meaningfully improve outcomes for patients with relapsed or refractory AML: https://bit.ly/4foEEtr

05/15/2026

Early blinded results continue to show a 40% composite complete remission rate across a difficult-to-treat AML patient population in Moleculin's pivotal MIRACLE trial, with the first interim unblinding expected in June 2026 following achievement of the 45 subject enrollment milestone. Enrollment in the MIRACLE trial continues to advance on pace with the 90th subject expected in Q3 2026. Read more: https://bit.ly/4foEEtr

05/15/2026

Moleculin today reported financial results for the first quarter ended March 31, 2026 and provided a clinical update on the pivotal MIRACLE Phase 2B/3 trial evaluating Annamycin in combination with cytarabine (“AnnAraC”) for the treatment of relapsed/refractory acute myeloid leukemia (AML). Read more: https://bit.ly/4foEEtr

05/14/2026

Stay up to date with .

Sign up to receive the latest company news, research updates and developments directly to your inbox:
https://bit.ly/3vdevGH